Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company, has seen an increase of 9.20% in the premarket trading session. As a result, NERV stock is trading at $1.0 at the time of this writing. The increase has come after the company announced the results from its bioequivalence study. On Thursday, NERV stock closed the day at $1.74 after declining some 1.74% during the regular trading session.
NERV announced results from the bioequivalence study
In the late hours of Thursday, NERV announced the results from the bioequivalence study. The study compared the oluperidone formulations used in its late-stage Phase 2b and Phase 3 trials and its commercial formulations. According to the company, the study met all of the key pharmacokinetic (PK) objectives. The data from the study depicted bioequivalence across numerous formulations. To evaluate bioequivalence between various formulations, some plasma pharmacokinetic parameters are used, like AUClast, AUCinf and Cmax. The efficiency of roluperidone is determined by the plasma exposure of the drug. In contrast to that, the safety margins were improved considerably by the reduction of Cmax. The 45 subjects completed all of the study periods out of a total of 48 subjects randomized. The male subjects formed 69% of the participants. 75% of subjects were white. The median age of those under study was 36 years. All of the participants had a negative SARS-CoV2 status at the start of the study.
Q2 2021 financial results
On 2nd August, NERV reported the quarterly results for the second quarter of the fiscal year 2021, which ended 30th June 2021. According to the details, the company had cash and cash equivalents of $74.21 million on 30th June. The total assets stood at $105.32 million, while total liabilities were $69.15 million. The total operating expenses bore by the company during the period stood at $8.96 million. During the equivalent period of 2020, the operating expenses stood at $11.66 million. The net loss for the period stood at $10.58 million. For an equivalent period of 2020, the net income for the company stood at $29.5 million. The net loss per basic and diluted share during the period stood at $0.25. During the equivalent period of 2020, the net income per basic and diluted share was $0.75 and $0.73, respectively.
What future holds in store for NERV?
Stats reveal a grim picture for NERV stock. The stock has declined by 5% during last one week and more than 25% during last one quarter. But analysts are hopeful that the optimistic results of the company’s study on Schizophrenia could provide a major boost to its financial stature. So, potential investors should keep a close watch on the developments of NERV stock.